Type 2 Immunity Is Not a Mistake. It Is 500 Million Years Old.

Allergy feels like a malfunction. A peanut, a pollen grain, a cat — harmless things provoke sneezing, wheeze, hives, anaphylaxis. It is tempting to treat Type 2, or T2, immunity as the immune system misfiring.

A major new review argues for almost the opposite reading: T2 immunity is ancient, purposeful, and deeply woven into how bodies defend barriers and repair tissue. Allergy is what happens when that old system is triggered in the wrong place, at the wrong time, by the wrong thing — or fails to switch off.

That reframing matters, because the same pathways we now block with powerful biologics are also the pathways that keep skin, gut, and lungs intact.

1. Older Than Vertebrates, Older Than Lungs

Jiménez-Saiz and colleagues trace T2 immunity back roughly 500 million years — to a time near the origin of adaptive immunity itself. 

The logic is evolutionary, not just historical. The best-described inducers of T2 cytokines are helminths, parasites from animal phyla that diverged over a billion years ago. The interaction between vertebrate immunity and at least some major helminth groups extends back hundreds of millions of years, near to when adaptive immunity first evolved. 

In other words, T2 did not evolve to fight pollen. It evolved to fight things too large to be phagocytosed, too destructive to be ignored, and too mobile to be contained by a single cell.

That explains its signature toolkit:

IL-4 and IL-13: drive alternative macrophage activation, goblet-cell mucus, smooth-muscle contraction, and IgE/IgG4 class switching

IL-5: matures, recruits, and sustains eosinophils

IgE: arms mast cells and basophils for rapid expulsion responses

Eosinophils, mast cells, basophils, and ILC2s: innate and adaptive cells that act at barriers

This is not primarily a “kill the microbe” program like Type 1 immunity. It is a “contain, expel, and repair” program.

2. Repair Was Probably the Original Job

One of the most influential ideas in the field, from Allen and Wynn, is that Th2 immunity evolved as an adaptive tissue-repair response to tissue-destructive pathogens. 

In that model:

Th1 immunity, characterized by IFN-γ production, evolved to control innate anti-microbial pathways, while the host defense system that evolved to cope with metazoan parasites was the innate tissue repair process, now controlled by Th2 cells. 

Helminths cause extensive tissue damage as they migrate, feed, and burrow. A purely destructive immune response would make the damage worse. The host needed a system that could do three things at once:

Limit the parasite — wall it off, expel it, make the tissue inhospitable

Limit collateral damage — dampen Type 1 inflammation

Rebuild the barrier — promote collagen deposition, epithelial proliferation, angiogenesis, and wound closure

That is why T2 cytokines are so closely tied to fibrosis, mucus, and remodeling. The same IL-13 that thickens airway walls in asthma helps seal a gut wound after a parasite passes through. The same eosinophils that inflame the esophagus in eosinophilic esophagitis help regulate intestinal homeostasis and tissue remodeling in health.

T2 immunity, in this view, is less like an army and more like a damage-control and construction crew — one that arrived early, stayed, and was later co-opted for allergy.

3. A Very Recent Brake: Human-Type IgG4

If T2 immunity is ancient, its regulatory brakes are surprisingly new.

Jiménez-Saiz et al. note that fully functional human-type IgG4 emerged in great apes within the last ∼10 million years. IgG4-like proteins are found across great apes, including humans, bonobos, chimpanzees, gorillas, and orangutans. 

Why does that matter?

IgG4 is unusual. It binds poorly to complement, binds weakly to activating Fc receptors, and can undergo Fab-arm exchange, making it functionally monovalent and largely non-inflammatory. In allergy, it is often the “tolerant” antibody: high IgG4 relative to IgE is associated with desensitization during immunotherapy and with natural tolerance to foods and venoms.

The evolutionary story the review suggests is stepwise co-evolution: first came the powerful T2 effector machinery, then — much later — increasingly sophisticated regulatory circuits to restrain it.

That timing is suggestive. Humans did not get a brand-new T2 system in the last 10 million years. We got a better off-switch. When that off-switch fails or is bypassed, the ancient system runs unchecked.

4. The Barrier Is the Battlefield

The modern expansion of T2 disease cannot be explained by genes alone. Jiménez-Saiz et al. place the epithelial barrier, microbiome, and immune interaction at the center.

Epithelial cells are not passive bricks. When damaged by detergents, pollutants, proteases, viruses, or microbes, they release alarmins — TSLP, IL-25, and IL-33 — that activate ILC2s and dendritic cells and bias the response toward T2.

The microbiome shapes that threshold. Germ-free mice, for example, show altered intestinal eosinophilia, and eosinophil-deficient mice develop intestinal fibrosis and reduced allergic sensitization — evidence that eosinophils help regulate gut immune homeostasis, not just drive inflammation.

Once the barrier is leaky, allergens reach the submucosa, dendritic cells present them in a T2-biased context, and the system learns to treat a harmless protein as a parasite-like threat. That is the epithelial barrier hypothesis in action: modern exposures erode barriers, the microbiome shifts, and an ancient repair system is repeatedly alarmed.

This helps explain why T2 diseases now cluster together and expand beyond classic allergy:

Asthma, atopic dermatitis, allergic rhinitis, food allergy

Chronic rhinosinusitis with nasal polyps

Eosinophilic esophagitis and other eosinophilic gastrointestinal diseases

Chronic spontaneous urticaria

Prurigo nodularis and other itch-driven diseases

They are not separate diseases that happen to share cytokines. They are different barrier organs expressing the same old program.

5. The Biologic Revolution — And Its Uncomfortable Question

The last two decades have transformed severe T2 disease. Biologics now target the pathway at multiple levels:

IgE: omalizumab binds free IgE and prevents mast cell and basophil activation 

IL-5 / IL-5Rα: mepolizumab, reslizumab, and benralizumab reduce eosinophil survival and activation 

IL-4Rα: dupilumab blocks both IL-4 and IL-13 signaling 

TSLP: tezepelumab blocks an upstream epithelial alarmin, effective even without classic T2 biomarkers 

IL-31: emerging anti-IL-31 approaches target itch, a core driver of eczema and prurigo nodularis

For patients with severe asthma, eczema, nasal polyps, or food allergy, these drugs have been life-changing: fewer exacerbations, less oral corticosteroid use, better quality of life.

But Jiménez-Saiz et al. raise the question that follows logically from the evolutionary story: what happens when we suppress a homeostatic system for years or decades?

If T2 immunity evolved for parasite defense and tissue protection/repair, sustained blockade is not just turning off allergy. It is also turning down:

Mucosal barrier repair

Eosinophil-mediated tissue homeostasis

Anti-parasite and anti-venom defense

Wound-healing and remodeling pathways

Regulatory feedback involving IgG4 and IL-10

That does not mean biologics are unsafe. It means they are not biologically neutral. Long-term safety data are still accumulating, especially for upstream blockade of TSLP or combined IL-4/IL-13 blockade started in childhood and continued for decades.

The right question is not “should we use these drugs?” For severe disease, the answer is clearly yes. The question is: how do we use them precisely, for the right patient, for the right duration, with monitoring for what T2 was originally for?

That could mean biomarker-guided de-escalation, intermittent dosing, barrier-restoring strategies alongside biologics, and attention to infection, wound healing, and parasite exposure in endemic regions.

6. Allergy as an Evolutionary Mismatch

Put together, the review offers a coherent mismatch model:

Ancient system + modern environment = modern disease.

We removed most helminths, changed our microbiomes, increased barrier-disrupting exposures, and kept the T2 machinery. The system, deprived of its original targets, now responds to dust mites, peanuts, and pollen with a program designed for worms and wounds.

It makes it a real biological trade-off: the same system that saved our ancestors from parasites and helped heal their guts and lungs now overreacts in a world of clean water, processed food, detergents, air pollution, and antibiotics.

Understanding that trade-off changes the goal. The aim is not to erase T2 immunity. It is to re-tune it — restore barriers, restore microbial signals, restore tolerance, and use biologics as precision tools, not permanent off-switches.

T2 immunity survived 500 million years because it worked. Our job now is not to defeat it, but to learn how to live with it again.

References

Jiménez-Saiz R, Iborra S, Blanco C, González-Pérez R, et al. Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases. Allergy. 2026 Sep 9. doi: 10.1111/all.70512. 

Allen JE, Wynn TA. Evolution of Th2 Immunity: A Rapid Repair Response to Tissue Destructive Pathogens. PLoS Pathogens. 2011;7(5):e1002003. doi:10.1371/journal.ppat.1002003. 

Maizels RM, et al. Immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology. Review series on helminths, immune modulation and the hygiene hypothesis. 

Tracing the evolutionary pathway of IgG4: Implications for immune tolerance and regulation. PMC. 2025 Jan. Comprehensive in silico analysis across great apes provided insights into IgG4-like proteins. 

Biologic Therapies for Severe Asthma: Current Insights and Future Directions. Current biologics include omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (anti-IL-5 receptor), dupilumab (anti-IL-4/IL-13), and tezepelumab (anti-TSLP).